Although such molecules have been demonstrated to reduce the viability of RTK-driven tumor cells through inhibition of MAPK signaling in cells that have normal SHP2 alleles, we lack an understanding of whether SHP2 mutations observed in patients with PTPN11-mutated malignancies can be effectively targeted by currently available allosteric inhibitors. The gene discussed is PTPN11; the disease is neoplasm.